Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

Pelthos Q2 2026: Zelsuvmi revenue up 45% QoQ; Horizon loan fuels expansion

Aug 13, 2026, 7:14 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Q2 revenue growth and unit adoption validate the Zelsuvmi ramp; liquidity from Horizon reduces near-term funding risk and supports upcoming launches, potentially lifting investor confidence and multiples if growth remains on track.

AI summary

What happened, with direct paths to the underlying reporting

Pelthos reported Q2 2026 results with Zelsuvmi net product revenue of $15.4 million, up 45% from Q1. Units dispensed rose 48% QoQ to 11,925 across 4,571 prescribers, with cumulative prescriptions surpassing 25,000 since launch in July 2025. The company secured a $50 million Horizon loan facility, drawing $30 million and potentially access to an additional $10 million, supporting expected launches of Xepi in 2027 and Xeglyze later in 2027, while maintaining a cash balance of $24.2 million as of 6/30/2026.

Zelsuvmi Q2 2026 net product revenue rose 45% QoQ to $15.4M.
11,925 Zelsuvmi units dispensed in Q2 2026; 4,571 unique prescribers; +48% QoQ.
Cumulative Zelsuvmi prescriptions exceed 25,000 since July 2025 launch.
Horizon loan facility: $50M; drawn $30M; potential extra $10M; cash $24.2M.
Xepi (Q1 2027) and Xeglyze (Q3 2027) launches geplanned; management optimistic.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.